Internal Medicine, Cardiovascular Disease · Boston, MA
NPI
1144773136
Since 2016
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
75 Francis St
Boston, MA, 02115
Phone (617) 732-5500
Groups this clinician bills Medicare through
Medicare paid, 2024
$66K
901 services
Medicare patients, 2024
390
Average age 77
Drug cost, 2024
$42.5M
3,140 prescriptions
Company payments, 2025
$42K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sarah Cuddy was code 99215 (office e&m - established), 355 times for 223 patients. In total Sarah Cuddy billed 901 services in 19 codes, and Medicare paid $66K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-01-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 355 | 223 | $106.19 | $38K |
| 93306 Echocardiography (TTE/TEE) | Facility | 193 | 188 | $50.63 | $9,772 |
| 93356 Echocardiography (TTE/TEE) | Facility | 150 | 147 | $8.58 | $1,287 |
| 94621 Pulmonary Function Testing | Facility | 62 | 62 | $53.06 | $3,290 |
| 99205 Office E&M - New | Facility | 36 | 36 | $146.30 | $5,267 |
| 99214 Office E&M - Established | Facility | 32 | 30 | $67.25 | $2,152 |
| 75561 MRI/MRA - Other | Facility | 32 | 32 | $99.34 | $3,179 |
By year: 2022 $88K for 1,883 services; 2023 $79K for 1,492 services; 2024 $66K for 901 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sarah Cuddy prescribed most often to Medicare patients was Vyndamax (Tafamidis), with 1,675 prescriptions and refills. In total Sarah Cuddy wrote 3,140 Medicare prescriptions that cost $42.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Vyndamax Tafamidis | 1,675 | 1,805 | 189 | $39.5M |
| Eliquis Apixaban | 237 | 381 | 44 | $216K |
| Jardiance Empagliflozin | 227 | 426 | 62 | $245K |
| Furosemide Generic | 128 | 252 | 43 | $718 |
| Vyndaqel Tafamidis Meglumine | 109 | 113 | 18 | $2.4M |
| Spironolactone Generic | 87 | 214 | 24 | $530 |
| Torsemide Generic | 83 | 212 | 35 | $2,479 |
| Farxiga Dapagliflozin Propanediol | 71 | 163 | 18 | $89K |
| Metoprolol Succinate Generic | 59 | 161 | 23 | $1,147 |
| Atorvastatin Calcium Generic | 57 | 163 | 18 | $1,479 |
| Amiodarone Hcl Generic | 51 | 125 | 15 | $1,735 |
| Xarelto Rivaroxaban | 29 | 37 | Under 11 | $21K |
| Diflunisal Generic | 28 | 61 | Under 11 | $1,510 |
| Rosuvastatin Calcium Generic | 24 | 66 | Under 11 | $446 |
| Losartan Potassium Generic | 23 | 69 | Under 11 | $288 |
Brand drugs: 2,379 claims; generic drugs: 761 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sarah Cuddy $42K ($42K in general payments such as food, travel and fees) from 8 companies. The largest payer was Novo Nordisk AS with $16K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.